Tyco's (NYSE: TYC) before the bell earnings announcement has all the wirehouses and analysts telling investors different stories. Due to a variety of "one-time charges," deciphering the true earnings per share for the company takes detective work.
The primary one-time charge for the company was the settlement of a class-action lawsuit related to the company's former CEO and convicted felon Dennis Kozlowski.
But analysts and companies tend to not count one-time charges simply because, as the name implies, they only occur one time. Due to this fact, the theory is that companies should back these charges out in order to give a more normalized and realistic figure.
Tyco's EPS figure came in at 55 cents per share ex-one time charges. This figure, compared to last year's 49 cents per share and above estimates for 48 cents per share seems to be a rather significant beat. However, there's still a variety of opinions on this figure -- one analyst report I read came out with an "EPS from continuing operations figure around 48 cents per share."
Basically, the Tyco earnings report is so confusing that you better really understand why you own this stock or you could get hurt. The company, even after breaking-up into three parts, remains a very interesting segment with many moving parts. As a result, it seems like every earnings report is loaded with accounting jargon, backing out certain figures, not counting certain figures, and so on. While I'm certainly not asserting that the company is doing anything wrong, I think there are certainly easier situations to analyze.
Last updated: February 13, 2012: 10:20 AM
Hot Stocks
DailyFinance Headlines
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- SanDisk volatility low into analyst day and sales outlook
- Obama budget requests increase in Pell Grants, Inside Higher Education says
- Stoneridge sees 2012 EPS $1.10-$1.30 vs. consensus $1.13
- Stoneridge Q2 results include $1.72/sh in gains
- Stoneridge reports Q4 diluted EPS $1.56 vs. consensus 22c
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

